Protean PTEN: Form and function

被引:342
作者
Waite, KA
Eng, C
机构
[1] Ohio State Univ, Human Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] Ohio State Univ, Clin Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA
关键词
D O I
10.1086/340026
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Germline mutations distributed across the PTEN tumor-suppressor gene have been found to result in a wide spectrum of phenotypic features. Originally shown to be a major susceptibility gene for both Cowden syndrome (CS), which is characterized by multiple hamartomas and an increased risk of breast, thyroid, and endometrial cancers, and Bannayan-Riley-Ruvalcaba syndrome, which is characterized by lipomatosis, macrocephaly, and speckled penis, the PTEN hamartoma tumor syndrome spectrum has broadened to include Proteus syndrome and Proteus-like syndromes. Exon 5, which encodes the core motif, is a hotspot for mutations likely due to the biology of the protein. PTEN is a major lipid 3-phosphatase, which signals down the PI3 kinase/AKT proapoptotic pathway. Furthermore, PTEN is a protein phosphatase, with the ability to dephosphorylate both serine and threonine residues. The protein-phosphatase activity has also been shown to regulate various cell-survival pathways, such as the mitogen-activated kinase (MAPK) pathway. Although it is well established that PTEN's lipid-phosphatase activity, via the PI3K/AKT pathway, mediates growth suppression, there is accumulating evidence that the protein-phosphatase/MAPK pathway is equally important in the mediation of growth arrest and other crucial cellular functions.
引用
收藏
页码:829 / 844
页数:16
相关论文
共 122 条
[1]   Balanced translocation of 10q and 13q, including the PTEN gene, in a boy with a human chorionic gonadotropin-secreting tumor and the Bannayan-Riley-Ruvalcaba syndrome [J].
Ahmed, SF ;
Marsh, DJ ;
Weremowicz, S ;
Morton, CC ;
Williams, DM ;
Eng, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (12) :4665-4670
[2]  
Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.3.CO
[3]  
2-I
[4]   PTEN mutations are uncommon in Proteus syndrome [J].
Barker, K ;
Martinez, A ;
Wang, R ;
Bevan, S ;
Murday, V ;
Shipley, J ;
Houlston, R ;
Harper, J .
JOURNAL OF MEDICAL GENETICS, 2001, 38 (07) :480-481
[5]  
Biesecker LG, 1999, AM J MED GENET, V84, P389, DOI 10.1002/(SICI)1096-8628(19990611)84:5<389::AID-AJMG1>3.0.CO
[6]  
2-O
[7]  
Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO
[8]  
2-0
[9]   PTEN expression is reduced in a subset of sporadic thyroid carcinomas:: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 [J].
Bruni, P ;
Boccia, A ;
Baldassarre, G ;
Trapasso, F ;
Santoro, M ;
Chiappetta, G ;
Fusco, A ;
Viglietto, G .
ONCOGENE, 2000, 19 (28) :3146-3155
[10]  
Carethers JM, 1998, CANCER RES, V58, P2724